Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Minotti

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
Cardio-Oncology (London, England)|December 9, 2020
In ®Entresto we trustMassimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna, et al.
Cardio-Oncology (London, England)|February 3, 2021
An Invitation from the Editors of Cardio-OncologySteven E Lipshultz, Giorgio Minotti, Joseph Carver, et al.
Cardiovascular Toxicology|May 7, 2014
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradoxFabio Cacciapaglia, Emanuela Salvatorelli, Giorgio Minotti, et al.
Chemotherapy|November 11, 2022
Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac DeathGiuseppe Boriani, Pierantonio Menna, Riccardo Morgagni, et al.
Heart (British Cardiac Society)|February 26, 2026
Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotectionMassimiliano Camilli, Teresa Lopez-Fernandez, Giorgio Minotti, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 16, 2009
Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heartEmanuela Salvatorelli, Pierantonio Menna, Mario Lusini, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2017
Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose DoxorubicinEmanuela Salvatorelli, Pierantonio Menna, Massimo Chello, et al.
Biochemistry|June 5, 2002
Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitaseGaetano Cairo, Raffaella Ronchi, Stefania Recalcati, et al.
Pharmacological Reviews|June 1, 2004
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityGiorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 10, 2020
Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological AppraisalGiorgio Minotti, Pierantonio Menna, Massimiliano Camilli, et al.
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Cardio-Oncology (London, England)|December 9, 2020
In ®Entresto we trustMassimiliano Camilli, Marco Giuseppe Del Buono, Pierantonio Menna, et al.
Cardio-Oncology (London, England)|February 3, 2021
An Invitation from the Editors of Cardio-OncologySteven E Lipshultz, Giorgio Minotti, Joseph Carver, et al.
Cardiovascular Toxicology|May 7, 2014
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradoxFabio Cacciapaglia, Emanuela Salvatorelli, Giorgio Minotti, et al.
Chemotherapy|November 11, 2022
Ibrutinib and Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias/Sudden Cardiac DeathGiuseppe Boriani, Pierantonio Menna, Riccardo Morgagni, et al.
Heart (British Cardiac Society)|February 26, 2026
Pharmacological strategies to prevent cancer therapy-related cardiovascular toxicity: the road to personalised cardioprotectionMassimiliano Camilli, Teresa Lopez-Fernandez, Giorgio Minotti, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 16, 2009
Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heartEmanuela Salvatorelli, Pierantonio Menna, Mario Lusini, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 2017
Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose DoxorubicinEmanuela Salvatorelli, Pierantonio Menna, Massimo Chello, et al.
Biochemistry|June 5, 2002
Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitaseGaetano Cairo, Raffaella Ronchi, Stefania Recalcati, et al.
Pharmacological Reviews|June 1, 2004
Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicityGiorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 10, 2020
Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological AppraisalGiorgio Minotti, Pierantonio Menna, Massimiliano Camilli, et al.
Pageof 13